Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
Investing.com - Leerink Partners has raised its price target on Johnson & Johnson (NYSE:JNJ) to $201 from $171 while maintaining a Market Perform rating on the healthcare giant.
The price target increase follows Johnson & Johnson’s strong third-quarter 2025 results, with the company maintaining its 2025 earnings per share guidance. Leerink slightly increased its 2026 EPS estimate from $11.42 to $11.47, while maintaining its 2025 EPS estimate of $10.87.
Johnson & Johnson’s CFO Wolk has targeted 2026 topline growth of 5% or more and EPS above $11.44. The company also reiterated its five-year (2025-2030) compound annual growth rate target for revenue growth of 5-7%.
Management highlighted peak sales targets for key products, including Tremfya ($10 billion+), Rybrevant ($5 billion+), Inlexzo ($5 billion+), icotrokinra ($5 billion+), and Caplyta ($5 billion+). The company expressed high confidence in positive Daubert rulings on talc litigation in the first quarter of 2026.
The planned separation of Johnson & Johnson’s Orthopedics business is expected to improve MedTech top-line growth and enhance operating margin by at least 75 basis points based on year-to-date 2025 performance.
In other recent news, Johnson & Johnson reported its third-quarter earnings for 2025, exceeding analysts’ expectations with an earnings per share of $2.80, surpassing the forecasted $2.76. The company also reported revenue of $23.99 billion, which was higher than the anticipated $23.76 billion. Analysts have responded positively to these results, with RBC Capital maintaining an Outperform rating and a $209 price target, noting strong operational sales growth driven by the MedTech segment. Similarly, Raymond James raised its price target to $209, expressing optimism about the company’s future growth despite challenges such as the loss of exclusivity for Stelara. Wolfe Research also increased its price target to $225, citing strong commercial execution and expected margin expansion. Stifel raised its price target to $190, acknowledging Johnson & Johnson’s better-than-expected earnings and positive business outlook. These developments highlight a period of robust performance and strategic growth for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.